Zenavod (DFD-09) is the new Generic Oracea – sadly no


News today that Dr. Reddy’s subsidiary Promius Pharma has gained tentative approval for their 40mg formulation of doxycycline for the papules and pustles of rosacea.

Before we get too excited about the real possibility of the availability of a generic form of Oracea, the announcement tells us that the approval is “subject to an automatic stay of final approval for up to 30 months pending a patent infringement process under the Drug Price Competition and Patent Term Restoration Act (“Hatch Waxman”).”

Indeed we know that Galderma will vigorously defend the patents that cover Oracea. Galderma asserts that Oracea has patent protection via U.S. Patent No. 7,749,532, which expires Dec 19, 2027.

So it will be more than 2 years before we know how much longer we will need to wait. Even at the expiration of the 30 months, we may still be left waiting until the end fo 2027 anyway.

Companies like Promius exist to make money on generic alternatives of prescription treatments, but one has to wonder how much time, effort and money is required to be able to market a product against industry heavyweights like Galderma.

We can only hope that a cheaper generic form of Oracea does eventually become available for rosacea sufferers who are learning that Oracea is already too expensive, and only increasing in price.

Press Release

Dr. Reddy’s Laboratories Receives USFDA Tentative Approval for Zenavod (doxycycline) Capsules, 40 mg for the Treatment of Rosacea

February 01, 2016 02:33 AM Eastern Standard Time


Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today the U.S. Food and Drug Administration (US FDA) tentative approval for Zenavod (doxycycline) Capsules, 40 mg.

Zenavod is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

Promius Pharma, LLC, the U.S. subsidiary of India’s Dr. Reddy’s Laboratories will be responsible for commercializing Zenavod in the U.S. market.

Promius Pharma is probably best know to rosacea sufferers via the availability of Promiseb Topical Cream in the US. Promiseb, a treatment for seborrheic dermatitis, is noteworthy as it prescription only but has no active ingredients.

DFD-09 Update

We know from the 2015 Investor Day presentation some more background on how Dr Reddy and Promius Pharma are positioning DFD-09 as a new product, related to, but differentiated from Oracea.



  • Modified release doxycycline indicated for rosacea
  • Label similar to Oracea but pursuing claims for dosage without regard to meals.
  • Intent to supplement NDA with additional clinical trials to drive differentiation

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

2 Reader Comments

  1. britstuff says:

    “Promiseb, a treatment for seborrheic dermatitis, is noteworthy as it prescription only but has no active ingredients.”

    So its a placebo? Sorry – Fake?

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.